CN114225091B - Biological enzyme wound dressing and preparation method thereof - Google Patents
Biological enzyme wound dressing and preparation method thereof Download PDFInfo
- Publication number
- CN114225091B CN114225091B CN202111368827.4A CN202111368827A CN114225091B CN 114225091 B CN114225091 B CN 114225091B CN 202111368827 A CN202111368827 A CN 202111368827A CN 114225091 B CN114225091 B CN 114225091B
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- deionized water
- wound dressing
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 31
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 claims abstract description 86
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000843 powder Substances 0.000 claims abstract description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000008367 deionised water Substances 0.000 claims abstract description 44
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 44
- 235000004338 Syringa vulgaris Nutrition 0.000 claims abstract description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 34
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940088598 enzyme Drugs 0.000 claims abstract description 32
- 239000004365 Protease Substances 0.000 claims abstract description 24
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 17
- 108091005804 Peptidases Proteins 0.000 claims abstract description 17
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 17
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 17
- 108090000190 Thrombin Proteins 0.000 claims abstract description 17
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960000458 allantoin Drugs 0.000 claims abstract description 17
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 17
- 229940022757 asiaticoside Drugs 0.000 claims abstract description 17
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000001110 calcium chloride Substances 0.000 claims abstract description 17
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 239000011780 sodium chloride Substances 0.000 claims abstract description 17
- 229960004072 thrombin Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 77
- 239000000243 solution Substances 0.000 claims description 40
- 241001104043 Syringa Species 0.000 claims description 38
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 239000006228 supernatant Substances 0.000 claims description 36
- 241000934856 Daphne Species 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 32
- 235000019441 ethanol Nutrition 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 26
- 241001310717 Daphne genkwa Species 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 20
- 239000000706 filtrate Substances 0.000 claims description 19
- 235000019419 proteases Nutrition 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000004140 cleaning Methods 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 8
- 239000004382 Amylase Substances 0.000 claims description 7
- 108010065511 Amylases Proteins 0.000 claims description 7
- 102000013142 Amylases Human genes 0.000 claims description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 7
- 108090000526 Papain Proteins 0.000 claims description 7
- 235000019418 amylase Nutrition 0.000 claims description 7
- 229940055729 papain Drugs 0.000 claims description 7
- 235000019834 papain Nutrition 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 6
- 239000001180 angelica archangelica l. root extract Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 29
- 206010052428 Wound Diseases 0.000 abstract description 28
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 12
- 230000024245 cell differentiation Effects 0.000 abstract description 3
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000029663 wound healing Effects 0.000 abstract description 2
- 244000297179 Syringa vulgaris Species 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 20
- 241000628997 Flos Species 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 2
- 108010059820 Polygalacturonase Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108010093305 exopolygalacturonase Proteins 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
The invention belongs to the technical field of wound dressings, and particularly discloses a biological enzyme wound dressing and a preparation method thereof. The biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.01 to 0.06 portion of protease, 0.05 to 0.2 portion of collagen peptide, 0.1 to 0.25 portion of triethanolamine, 0.2 to 0.8 portion of asiaticoside, 0.2 to 0.7 portion of thrombin freeze-dried powder, 0.4 to 1 portion of lilac daphne flower bud extract, 0.5 to 1.2 portions of angelica dahurica extract, 1 to 1.6 portions of sodium chloride, 1~2 portions of allantoin, 1~3 portions of Tween 60, 3~7 portions of glycerol, 6 to 15 portions of calcium chloride water solution and 65 to 80 portions of deionized water. The wound surface dressing has good antibacterial and anti-inflammatory effects and good biocompatibility, effectively promotes cell proliferation and differentiation, and promotes wound healing.
Description
Technical Field
The invention relates to the technical field of wound dressings, in particular to a biological enzyme wound dressing and a preparation method thereof.
Background
The wound surface is the damage of normal skin (tissue) caused by external injury factors such as surgery, external force, heat, current, chemical substances, low temperature and internal factors of the body such as local blood supply disorder. Often accompanied by a breakdown in the integrity of the skin and a loss of a certain amount of normal tissue, while the normal function of the skin is impaired.
In order to avoid wound infection, the wound dressing should have good antibacterial activity, and the current dressing achieves the antibacterial effect by adding chemical medicines into the dressing. Chemical drugs have certain side effects and irritation; when used in large area or frequently used, the components can be absorbed by the body, and toxic and side effects are generated, which is especially unsafe for children.
Disclosure of Invention
The invention provides a biological enzyme wound dressing and a preparation method thereof, wherein the dressing has a good antibacterial effect and good biocompatibility.
The invention adopts the following technical scheme for solving the technical problems:
a biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.01 to 0.06 portion of protease, 0.05 to 0.2 portion of collagen peptide, 0.1 to 0.25 portion of triethanolamine, 0.2 to 0.8 portion of asiaticoside, 0.2 to 0.7 portion of thrombin freeze-dried powder, 0.4 to 1 portion of lilac daphne flower bud extract, 0.5 to 1.2 portions of angelica dahurica extract, 1 to 1.6 portions of sodium chloride, 1~2 portions of allantoin, 1~3 portions of Tween 60, 3~7 portions of glycerol, 6 to 15 portions of calcium chloride water solution and 65 to 80 portions of deionized water.
The biological enzyme wound dressing is prepared from the raw materials, is coated on silk cloth, and is freeze-dried to be used.
As a preferable scheme, the biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.02 to 0.06 part of protease, 0.05 to 0.12 part of collagen peptide, 0.18 to 0.25 part of triethanolamine, 0.2 to 0.6 part of asiaticoside, 0.3 to 0.7 part of thrombin freeze-dried powder, 0.5 to 1 part of lilac daphne flower bud extract, 0.8 to 1.2 parts of angelica dahurica extract, 1 to 1.5 parts of sodium chloride, 1.2 to 2 parts of allantoin, 1.5 to 3 parts of Tween 60, 4~7 parts of glycerol, 8 to 15 parts of calcium chloride aqueous solution and 70 to 80 parts of deionized water.
As a preferable scheme, the biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.05 part of protease, 0.1 part of collagen peptide, 0.2 part of triethanolamine, 0.5 part of asiaticoside, 0.6 part of thrombin freeze-dried powder, 0.8 part of lilac daphne flower bud extract, 1 part of radix angelicae extract, 1.2 parts of sodium chloride, 1.5 parts of allantoin, 2 parts of Tween 60, 6 parts of glycerol, 10 parts of calcium chloride aqueous solution and 8978 parts of deionized water.
As a preferred scheme, the preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 20-100 meshes to obtain daphne genkwa powder;
s2, adding the lilac daphne flower bud powder into 40-70wt% methanol solution, uniformly dispersing, carrying out ultrasonic treatment at 45-60 ℃ for 25-45min, filtering, taking filtrate, carrying out reduced pressure concentration at 40-50 ℃ and a vacuum degree of 0.04-0.06 Mpa until the filtrate has no alcohol smell, centrifuging, and taking supernatant;
and S3, adding the supernatant into deionized water, eluting the supernatant through an AB-8 macroporous adsorption resin column at the speed of 0.4 to 0.8BV/h, eluting the eluate through deionized water at the speed of 0.4 to 1.2BV, washing the eluate through 40 to 60wt% of ethanol solution at the speed of 1 to 2BV, collecting ethanol solution washing liquor, and drying to obtain the lilac daphne flower bud extract.
The lilac daphne flower bud extract with good antibacterial effect is obtained by cleaning, drying, crushing, ultrasonic extraction with methanol, concentration under reduced pressure, centrifugation and treatment with macroporous adsorption resin columns, and the lilac daphne flower bud extracts prepared by different preparation methods of the lilac daphne flower bud extract have different antibacterial effects.
As a preferable scheme, the ultrasonic treatment power in S2 is 400 to 800W.
As a preferable scheme, the weight ratio of the daphne genkwa pollen to the methanol solution in the S2 is 1:4 to 10, wherein the weight ratio of the supernatant to the deionized water in the S3 is 1:2~4.
As a preferred scheme, the preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the radix angelicae, and crushing the radix angelicae to 20-100 meshes to obtain radix angelicae powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 2 to 5 hours at 50 to 60 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:4 to 10;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment to obtain a microwave treatment solution;
s14, concentrating the microwave treatment solution at 40-50 ℃ and under the vacuum degree of 0.04-0.06 Mpa until the filtrate has no alcohol smell, and drying to obtain the angelica dahurica extract.
The angelica dahurica extract capable of remarkably inhibiting bacteria is prepared by cleaning, drying, crushing, enzymolysis, microwave-assisted alcohol extraction and reduced pressure concentration.
In the preparation method of the angelica dahurica extract, the bacteriostasis effects of the angelica dahurica extract prepared by adopting different enzymolysis solutions are different, the angelica dahurica extract prepared by the enzymolysis liquid composed of the hexadecyl trimethyl ammonium bromide, the papain, the amylase and the deionized water has good bacteriostatic effect, and the bacteriostatic effect is obviously reduced by adopting other enzymes.
Preferably, the enzymolysis liquid is prepared from 1~4 parts by weight of hexadecyl trimethyl ammonium bromide, 2~6 parts by weight of papain, 2~8 parts by weight of amylase and 80-95 parts by weight of deionized water.
As a preferable scheme, the microwave treatment power is 600 to 1000W, and the microwave treatment time is 15 to 25min.
The lilac daphne flower bud extract and the angelica dahurica extract prepared by the invention have obvious synergistic effect in the aspect of bacteriostasis.
The invention also provides a preparation method of the biological enzyme wound dressing, which comprises the following steps:
adding sodium chloride, allantoin, tween 60 and glycerol into deionized water, stirring at 200-600rpm for 40-100min, adding asiaticoside and calcium chloride aqueous solution, stirring at 200-600rpm for 20-60min, adding protease, collagen peptide, thrombin freeze-dried powder, a lilac daphne flower bud extract and an angelica root extract, stirring at 100-400rpm for 60-180min, adding triethanolamine, and stirring at 50-100rpm for 20-80min to obtain the biological enzyme wound dressing.
The invention has the beneficial effects that: the wound surface dressing has good antibacterial and anti-inflammatory effects and good biocompatibility, effectively promotes cell proliferation and differentiation, and promotes wound healing; the dressing is coated on silk cloth and is freeze-dried to be used, the lilac daphne flower bud extract and the angelica dahurica extract are added into a formula system to obviously improve the bacteriostatic effect, have obvious synergistic effect on the bacteriostatic aspect, are natural extracts and have good safety.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the present invention, the parts are all parts by weight unless otherwise specified.
Example 1
A biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.05 part of protease, 0.1 part of collagen peptide, 0.2 part of triethanolamine, 0.5 part of asiaticoside, 0.6 part of thrombin freeze-dried powder, 0.8 part of lilac daphne flower bud extract, 1 part of radix angelicae extract, 1.2 parts of sodium chloride, 1.5 parts of allantoin, 2 parts of Tween 60, 6 parts of glycerol, 10 parts of calcium chloride aqueous solution and 8978 parts of deionized water.
The preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 80 meshes to obtain daphne genkwa powder;
s2, adding flos genkwa powder into a 60wt% methanol solution, uniformly dispersing, carrying out ultrasonic treatment at 50 ℃ for 30min by 500W, filtering, taking filtrate, carrying out reduced pressure concentration at 45 ℃ and a vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, centrifuging at a rotating speed of 5000rpm for 8min, and taking supernatant; the weight ratio of the lilac daphne flower bud powder to the methanol solution is 1:5;
s3, adding the supernatant into deionized water, feeding the supernatant into an AB-8 macroporous adsorption resin column at 0.5BV/h, eluting the supernatant at the speed of 0.5BV/h, eluting the supernatant with deionized water for 1BV, washing the supernatant with 50wt% of ethanol solution for 1.2BV, collecting ethanol solution washing liquid, and drying the ethanol solution washing liquid to obtain the lilac daphne flower bud extract.
The weight ratio of the supernatant to the deionized water is 1:3.
the preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the angelica dahurica, and crushing the angelica dahurica to 50 meshes to obtain angelica dahurica powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 4 hours at 55 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:9;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment for 20min at 800W to obtain a microwave treatment solution; the weight ratio of the mixed solution to the absolute ethyl alcohol is 1:2;
s14, concentrating the microwave treatment liquid at 45 ℃ and under the vacuum degree of 0.05Mpa under reduced pressure until the filtrate has no alcohol taste, and drying to obtain the angelica dahurica extract.
The enzymolysis liquid is prepared from 2 parts by weight of hexadecyl trimethyl ammonium bromide, 4 parts by weight of papain, 5 parts by weight of amylase and 89 parts by weight of deionized water.
The preparation method of the biological enzyme wound dressing comprises the following steps:
adding sodium chloride, allantoin, tween 60 and glycerol into deionized water, stirring at 500rpm for 80min, adding asiaticoside and calcium chloride aqueous solution, stirring at 500rpm for 50min, adding protease, collagen peptide, thrombin lyophilized powder, flos Genkwa extract and radix Angelicae Dahuricae extract, stirring at 200rpm for 100min, adding triethanolamine, and stirring at 80rpm for 60min to obtain the biological enzyme wound dressing.
Example 2
A biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.01 part of protease, 0.2 part of collagen peptide, 0.1 part of triethanolamine, 0.8 part of asiaticoside, 0.2 part of thrombin freeze-dried powder, 1 part of lilac daphne flower bud extract, 0.5 part of angelica dahurica extract, 1.6 parts of sodium chloride, 1 part of allantoin, 3 parts of tween 60, 3 parts of glycerol, 15 parts of calcium chloride aqueous solution and 73.59 parts of deionized water.
The preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 20 meshes to obtain daphne genkwa powder;
s2, adding flos genkwa powder into a 50wt% methanol solution, uniformly dispersing, carrying out ultrasonic treatment at 50 ℃ for 30min by 500W, filtering, taking filtrate, carrying out reduced pressure concentration at 45 ℃ and a vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, centrifuging at a rotating speed of 5000rpm for 8min, and taking supernatant; the weight ratio of the lilac daphne flower bud powder to the methanol solution is 1:4;
s3, adding the supernatant into deionized water, feeding the supernatant into an AB-8 macroporous adsorption resin column at 0.5BV/h, eluting the supernatant at the speed of 0.5BV/h, eluting the supernatant by deionized water for 1BV, washing the supernatant by 60wt% ethanol solution for 1.2BV, collecting ethanol solution washing liquor, and drying the ethanol solution washing liquor to obtain the lilac daphne genkwa extract.
The preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the angelica dahurica, and crushing the angelica dahurica to 100 meshes to obtain angelica dahurica powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 3 hours at 55 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:4;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment for 20min at 800W to obtain a microwave treatment solution; the weight ratio of the mixed solution to the absolute ethyl alcohol is 1:2;
s14, concentrating the microwave treatment liquid at 45 ℃ and under the vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, and drying to obtain the angelica dahurica extract.
The enzymolysis liquid is prepared from 1 part by weight of hexadecyl trimethyl ammonium bromide, 6 parts by weight of papain, 2 parts by weight of amylase and 91 parts by weight of deionized water.
The preparation method of the biological enzyme wound dressing comprises the following steps:
adding sodium chloride, allantoin, tween 60 and glycerol into deionized water, stirring at 500rpm for 80min, adding asiaticoside and calcium chloride aqueous solution, stirring at 500rpm for 50min, adding protease, collagen peptide, thrombin lyophilized powder, flos Genkwa extract and radix Angelicae Dahuricae extract, stirring at 200rpm for 100min, adding triethanolamine, and stirring at 80rpm for 60min to obtain the biological enzyme wound dressing.
Example 3
A biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.06 part of protease, 0.05 part of collagen peptide, 0.2 part of triethanolamine, 0.2 part of asiaticoside, 0.7 part of thrombin freeze-dried powder, 0.4 part of daphne genkwa extract, 1.2 parts of angelica dahurica extract, 1 part of sodium chloride, 2 parts of allantoin, 2 parts of tween 60, 7 parts of glycerol, 6 parts of calcium chloride aqueous solution and 79.19 parts of deionized water.
The preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 100 meshes to obtain daphne genkwa powder;
s2, adding flos genkwa powder into 40wt% methanol solution, dispersing uniformly, performing ultrasonic treatment at 50 ℃ for 30min by 500W, filtering, taking filtrate, concentrating the filtrate under reduced pressure at 45 ℃ and a vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, centrifuging at a rotating speed of 5000rpm for 8min, and taking supernatant; the weight ratio of the lilac daphne flower bud powder to the methanol solution is 1:4;
s3, adding the supernatant into deionized water, feeding the supernatant into an AB-8 macroporous adsorption resin column at 0.5BV/h, eluting the supernatant at the speed of 0.5BV/h, eluting the supernatant by deionized water for 1BV, washing the supernatant by 60wt% ethanol solution for 1.2BV, collecting ethanol solution washing liquor, and drying the ethanol solution washing liquor to obtain the lilac daphne genkwa extract.
The preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the angelica dahurica, and crushing the angelica dahurica to 60 meshes to obtain angelica dahurica powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 3 hours at 55 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:4;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment for 20min at 800W to obtain a microwave treatment solution; the weight ratio of the mixed solution to the absolute ethyl alcohol is 1:2;
s14, concentrating the microwave treatment liquid at 45 ℃ and under the vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, and drying to obtain the angelica dahurica extract.
The enzymolysis liquid is prepared from 4 parts by weight of hexadecyl trimethyl ammonium bromide, 2 parts by weight of papain, 8 parts by weight of amylase and 86 parts by weight of deionized water.
The preparation method of the biological enzyme wound dressing comprises the following steps:
adding sodium chloride, allantoin, tween 60 and glycerol into deionized water, stirring at 500rpm for 80min, adding asiaticoside and calcium chloride aqueous solution, stirring at 500rpm for 50min, adding protease, collagen peptide, thrombin lyophilized powder, flos Genkwa extract and radix Angelicae Dahuricae extract, stirring at 200rpm for 100min, adding triethanolamine, and stirring at 80rpm for 60min to obtain the biological enzyme wound dressing.
Comparative example 1
Comparative example 1 is different from example 1 in that comparative example 1 uses the same amount of genkwa extract instead of the angelica dahurica extract, and the rest is the same.
A biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.05 part of protease, 0.1 part of collagen peptide, 0.2 part of triethanolamine, 0.5 part of asiaticoside, 0.6 part of thrombin freeze-dried powder, 1.8 parts of lilac daphne flower bud extract, 1.2 parts of sodium chloride, 1.5 parts of allantoin, 2 parts of tween 60, 6 parts of glycerol, 10 parts of calcium chloride aqueous solution and 8978 parts of deionized water.
Comparative example 2
Comparative example 2 is different from example 1 in that comparative example 2 uses the same amount of the angelica dahurica extract instead of the lilac daphne flower bud extract, and the rest is the same.
A biological enzyme wound dressing is prepared from the following raw materials in parts by weight: 0.05 part of protease, 0.1 part of collagen peptide, 0.2 part of triethanolamine, 0.5 part of asiaticoside, 0.6 part of thrombin freeze-dried powder, 1.8 parts of angelica dahurica extract, 1.2 parts of sodium chloride, 1.5 parts of allantoin, 2 parts of tween 60, 6 parts of glycerol, 10 parts of calcium chloride aqueous solution and 8978 parts of deionized water.
Comparative example 3
Comparative example 3 is different from example 1 in that the preparation method of yuanhuaba extract described in comparative example 3 is different from example 1, and the other steps are the same.
In the comparative example, in the preparation method of the lilac daphne flower bud extract, the same amount of deionized water is used for replacing a 60wt% methanol solution.
The preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 80 meshes to obtain daphne genkwa powder;
s2, adding flos genkwa powder into deionized water, uniformly dispersing, performing ultrasonic treatment at 50 ℃ for 30min by 500W, filtering, taking filtrate, performing reduced pressure concentration at 45 ℃ and a vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, centrifuging at a rotating speed of 5000rpm for 8min, and taking supernatant; the weight ratio of the lilac daphne flower bud powder to the deionized water is 1:5;
s3, adding the supernatant into deionized water, feeding the supernatant into an AB-8 macroporous adsorption resin column at 0.5BV/h, eluting the supernatant at the speed of 0.5BV/h, eluting the supernatant by deionized water for 1BV, washing the supernatant by 50wt% ethanol solution for 1.2BV, collecting ethanol solution washing liquor, and drying the ethanol solution washing liquor to obtain the lilac daphne genkwa extract.
The weight ratio of the supernatant to the deionized water is 1:3.
comparative example 4
Comparative example 4 is different from example 1 in that the preparation method of the angelica dahurica extract described in comparative example 4 is different from example 1, and the other steps are the same.
In the preparation method of the angelica dahurica extract in the comparative example, the enzymolysis liquid is prepared by adopting cellulase and pectinase.
The preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the angelica dahurica, and crushing the angelica dahurica to 50 meshes to obtain angelica dahurica powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 4 hours at 55 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:9;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment for 20min at 800W to obtain a microwave treatment solution; the weight ratio of the mixed solution to the absolute ethyl alcohol is 1:2;
s14, concentrating the microwave treatment liquid at 45 ℃ and under the vacuum degree of 0.05Mpa until the filtrate has no alcohol smell, and drying to obtain the angelica dahurica extract.
The enzymolysis liquid is prepared from 5.5 parts by weight of cellulase, 5.5 parts by weight of pectinase and 89 parts by weight of deionized water.
To further demonstrate the effect of the present invention, the following test methods were provided:
1. and (3) bacteriostatic test: the bacterial colony counting method was used to test the bacteriostatic effect of the dressings described in example 1~3 and comparative example 1~4 on escherichia coli (ATCC 25922) and staphylococcus epidermidis (ATCC 12228), and 500 μ L of the dressings of example 1~3 and comparative example 1~4 were prepared in each well of a 24-well plate under aseptic conditions. 500. Mu.L of the bacterial suspension (cell concentration: 10 in each case) 6 CFU/mL) was added to the corresponding well plate. Next, the 24-well plate was incubated in an incubator at 37 ℃ under a relatively humid atmosphere. And (4) calculating the number of colonies in the detection sample, calculating the bacteriostasis rate, and obtaining the test result shown in table 1.
As can be seen from Table 1, the dressing of the present invention has good bacteriostatic effect.
In the comparative example 1~3, it is known that the ratio of different raw materials and the preparation parameters of the angelica dahurica extract and the lilac daphne flower bud extract can affect the bacteriostatic effect.
Comparing example 1 with comparative example 1~2, it can be seen that the radix angelicae extract and the flos genkwa extract have a significant synergistic effect in bacteriostasis.
Compared with the comparative example 3, the daphne genkwa extracts prepared by different preparation methods of the daphne genkwa extracts have different antibacterial effects, and the daphne genkwa extracts prepared by the preparation method of the daphne genkwa extracts have better antibacterial effects than the daphne genkwa extracts prepared by other methods.
As can be seen from the comparison of example 1 and comparative example 4, in the preparation method of the angelica dahurica extract, the antibacterial effects of the angelica dahurica extract prepared by adopting different enzymatic hydrolysates are different, the angelica dahurica extract prepared by adopting the enzymatic hydrolysate consisting of the cetyl trimethyl ammonium bromide, the papain, the amylase and the deionized water according to the invention has good antibacterial effects, and the antibacterial effect is significantly reduced by adopting other enzymes.
2. Biocompatibility test (amplification test):
the cytotoxicity of the dressing prepared in example 1~3 was determined using NIH 3T3 cell viability and the biocompatibility of the hydrogel was evaluated. NIH 3T3 cells were first seeded at a density of 5000 cells/well in 96-well cell culture plates and cultured for 24h. 100 μ L of dressing was added to the wells of the plate and cell control wells without added sample were left in the plate and then incubated in the incubator for 2 days. After the incubation was completed, the solution in the plate was removed, 100. Mu.L of a phosphate buffer solution of MTT (0.5 mg/ml) was added, the plate was incubated at 37 ℃ in a humid environment for 4 hours, MTT in the wells was discarded, 100. Mu.L of DMSO was added each and mixed well by shaking at room temperature for 1min, and then the absorbance at 570nm was recorded by a microplate reader, and the test results are shown in Table 2.
Fold amplification = absorbance measured with dressing/absorbance measured without sample added.
TABLE 2 amplification factor
As can be seen from Table 2, the dressing of the present invention can effectively promote cell proliferation and differentiation, and has good biocompatibility.
In light of the foregoing description of preferred embodiments according to the invention, it is clear that many changes and modifications can be made by the person skilled in the art without departing from the scope of the invention. The technical scope of the present invention is not limited to the contents of the specification, and must be determined according to the scope of the claims.
Claims (7)
1. The biological enzyme wound dressing is characterized by being prepared from the following raw materials in parts by weight: 0.01 to 0.06 part of protease, 0.05 to 0.2 part of collagen peptide, 0.1 to 0.25 part of triethanolamine, 0.2 to 0.8 part of asiaticoside, 0.2 to 0.7 part of thrombin freeze-dried powder, 0.4 to 1 part of lilac daphne flower bud extract, 0.5 to 1.2 parts of angelica dahurica extract, 1 to 1.6 parts of sodium chloride, 1~2 parts of allantoin, 1~3 parts of Tween 60, 3~7 parts of glycerol, 6 to 15 parts of calcium chloride aqueous solution and 65 to 80 parts of deionized water;
the preparation method of the lilac daphne flower bud extract comprises the following steps:
s1, cleaning daphne genkwa, drying, and crushing to 20-100 meshes to obtain daphne genkwa powder;
s2, adding the lilac daphne flower bud powder into 40-70wt% methanol solution, uniformly dispersing, carrying out ultrasonic treatment at 45-60 ℃ for 25-45min, filtering, taking the filtrate, carrying out reduced pressure concentration at 40-50 ℃ and a vacuum degree of 0.04-0.06 MPa until the filtrate has no alcohol smell, centrifuging, and taking the supernatant;
s3, adding the supernatant into deionized water, feeding the supernatant into an AB-8 macroporous adsorption resin column at 0.4 to 0.8BV/h, eluting the supernatant at the speed of 0.4 to 1.2BV by using the deionized water, washing the supernatant at the speed of 1 to 2BV by using 40 to 60wt% of ethanol solution, collecting the ethanol solution washing liquor, and drying to obtain a lilac daphne flower bud extract;
the preparation method of the angelica dahurica extract comprises the following steps:
s11, cleaning and drying the radix angelicae, and crushing the radix angelicae to 20-100 meshes to obtain radix angelicae powder;
s12, adding the radix angelicae powder into the enzymolysis liquid, and carrying out enzymolysis for 2 to 5 hours at 50 to 60 ℃ to obtain a mixed liquid; the weight ratio of the angelica dahurica powder to the enzymolysis liquid is 1:4 to 10;
s13, adding the mixed solution into absolute ethyl alcohol, placing the absolute ethyl alcohol in a microwave extraction device, and performing microwave treatment to obtain a microwave treatment solution;
s14, concentrating the microwave treatment solution under reduced pressure at 40 to 50 ℃ and under the vacuum degree of 0.04 to 0.06MPa until the filtrate has no alcohol smell, and drying to obtain an angelica dahurica extract;
the enzymolysis liquid is prepared from 1~4 parts by weight of hexadecyl trimethyl ammonium bromide, 2~6 parts by weight of papain, 2~8 parts by weight of amylase and 80-95 parts by weight of deionized water.
2. The biological enzyme wound dressing according to claim 1, which is prepared from the following raw materials in parts by weight: 0.02 to 0.06 part of protease, 0.05 to 0.12 part of collagen peptide, 0.18 to 0.25 part of triethanolamine, 0.2 to 0.6 part of asiaticoside, 0.3 to 0.7 part of thrombin freeze-dried powder, 0.5 to 1 part of lilac daphne flower bud extract, 0.8 to 1.2 parts of angelica dahurica extract, 1 to 1.5 parts of sodium chloride, 1.2 to 2 parts of allantoin, 1.5 to 3 parts of Tween 60, 4~7 parts of glycerol, 8 to 15 parts of calcium chloride aqueous solution and 70 to 80 parts of deionized water.
3. The biological enzyme wound dressing according to claim 1, which is prepared from the following raw materials in parts by weight: 0.05 part of protease, 0.1 part of collagen peptide, 0.2 part of triethanolamine, 0.5 part of asiaticoside, 0.6 part of thrombin freeze-dried powder, 0.8 part of lilac daphne flower bud extract, 1 part of radix angelicae extract, 1.2 parts of sodium chloride, 1.5 parts of allantoin, 2 parts of Tween 60, 6 parts of glycerol, 10 parts of calcium chloride aqueous solution and 8978 parts of deionized water.
4. The biological enzyme wound dressing according to claim 1, wherein the ultrasonic treatment power in S2 is 400 to 800W.
5. The bio-enzyme wound dressing according to claim 1, wherein the weight ratio of lilac daphne flower bud powder to methanol solution in S2 is 1:4 to 10, wherein the weight ratio of the supernatant to the deionized water in the S3 is 1:2~4.
6. The biological enzyme wound dressing as claimed in claim 1, wherein the microwave treatment power is 600-1000W, and the microwave treatment time is 15-25min.
7. The method of making a bio-enzyme wound dressing of any one of claims 1~6 comprising the steps of:
adding sodium chloride, allantoin, tween 60 and glycerol into deionized water, stirring at 200-600rpm for 40-100min, adding asiaticoside and calcium chloride aqueous solution, stirring at 200-600rpm for 20-60min, adding protease, collagen peptide, thrombin freeze-dried powder, a lilac daphne flower bud extract and an angelica root extract, stirring at 100-400rpm for 60-180min, adding triethanolamine, and stirring at 50-100rpm for 20-80min to obtain the biological enzyme wound dressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111368827.4A CN114225091B (en) | 2021-11-18 | 2021-11-18 | Biological enzyme wound dressing and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111368827.4A CN114225091B (en) | 2021-11-18 | 2021-11-18 | Biological enzyme wound dressing and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114225091A CN114225091A (en) | 2022-03-25 |
| CN114225091B true CN114225091B (en) | 2022-12-02 |
Family
ID=80749968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111368827.4A Active CN114225091B (en) | 2021-11-18 | 2021-11-18 | Biological enzyme wound dressing and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114225091B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2346517T4 (en) * | 2008-10-31 | 2016-10-31 | Plant extract hydrolysates and antibacterial product containing the same | |
| WO2012157978A2 (en) * | 2011-05-17 | 2012-11-22 | 한국생명공학연구원 | Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis |
| CN113413375A (en) * | 2016-05-30 | 2021-09-21 | 傅远桥 | External-use medicine composition for treating various wound surfaces of skin and preparation method thereof |
| CN108619083A (en) * | 2018-04-19 | 2018-10-09 | 江苏理工学院 | A kind of medical reparation dressing of skin and preparation method thereof |
| CN109045349A (en) * | 2018-09-27 | 2018-12-21 | 四川省原子能研究院 | A kind of hydrogel skin wound dressing and preparation method thereof that antibacterial heal-promoting closes |
| CN113274438A (en) * | 2021-05-24 | 2021-08-20 | 上海交通大学 | Preparation and application of lilac daphne flower bud extract |
-
2021
- 2021-11-18 CN CN202111368827.4A patent/CN114225091B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114225091A (en) | 2022-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107857806B (en) | Sturgeon protamine and preparation method of sturgeon protamine polypeptide | |
| CN103385896B (en) | Preparation method of bacterial cellulose composite flavonoid compound | |
| CN108939140A (en) | Composition for hemostasis and medical hemostatic dressing | |
| CN117363678B (en) | Preparation method of peony fresh flower extracting solution | |
| CN114225091B (en) | Biological enzyme wound dressing and preparation method thereof | |
| CN120241547A (en) | A preparation method of Huangshan pine needle polyphenols and acne-removing and anti-inflammatory essence | |
| CN112426562A (en) | Pure natural medical dressing for promoting wound healing | |
| CN104887715A (en) | Bacillus subtilis preparation for spraying and application thereof | |
| CN113559311B (en) | Medical antibacterial hemostatic gel dressing and preparation method thereof | |
| CN106307538A (en) | Preparation method of aloe polysaccharide SOD active enzyme stock solution | |
| CN115252501B (en) | Acne-removing composition, preparation method and application | |
| CN114425074B (en) | A kind of antiviral and immunity-enhancing natural compound oral liquid and its preparation method | |
| CN114249666B (en) | Extraction method of betaine in phoenix tree leaves | |
| CN110279110A (en) | A kind of plant enzyme and preparation method thereof | |
| CN105126149A (en) | Composite chitosan application for medical use | |
| CN1087948C (en) | Fast-acting burn and scald treating liquid | |
| TWI573596B (en) | Ganoderma lucidum polysaccharide bio-wound dressing | |
| CN114848680A (en) | Composition for treating cow mastitis and preparation method thereof | |
| CN112336769A (en) | Natural plant fresh leaf extract composition and preparation for promoting wound healing and preparation method thereof | |
| CN112586735A (en) | Pseudo-ginseng compound enzyme with effects of promoting blood circulation and beautifying face and preparation method thereof | |
| CN105561382A (en) | Dendrobium officinale liquid woundplast and preparation method thereof | |
| CN106260354B (en) | Taibai Chinese yam and plum leaf substitute tea | |
| CN111514119A (en) | Adhesive bandage containing industrial hemp root extract and preparation method thereof | |
| CN112023110A (en) | Active antibacterial dressing based on bamboo fungus egg extract | |
| CN110507752B (en) | Acne-removing traditional Chinese medicine composition, preparation method thereof and acne-removing ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A biological enzyme wound dressing and its preparation method Effective date of registration: 20230629 Granted publication date: 20221202 Pledgee: Hunan Pingjiang Rural Commercial Bank Co.,Ltd. Pledgor: Chen Zhongping|Lancy Purcell Biotechnology (Guangzhou) Co.,Ltd. Registration number: Y2023980046730 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |